Zepbound's list price is around $1,086/month, but the manufacturer's self-pay vial program brings it to $299-$449/month depending on dose. Compounded tirzepatide runs lower still.
Luma Health's compounded tirzepatide is $297/month, flat, with your medical evaluation, provider visits, and shipping included, regardless of dose level.
Zepbound (tirzepatide) is FDA-approved specifically for chronic weight management — the weight-loss-labeled counterpart to Mounjaro, which is approved for type 2 diabetes. Both share the same active ingredient. Here's how Zepbound's real-world pricing breaks down across insurance, manufacturer self-pay, and compounded alternatives.
The List Price
Zepbound's retail list price runs approximately $1,059-$1,086 per month for the standard auto-injector pen, regardless of dose. As with most brand GLP-1 medications, this figure is rarely what patients actually end up paying once insurance, manufacturer programs, or compounded alternatives enter the picture. It's the reference point negotiations work down from rather than a realistic budget expectation for the vast majority of patients, insured or not.
With Commercial Insurance
If your commercial insurance plan covers Zepbound for weight management and you qualify for the manufacturer's savings card, your out-of-pocket cost can drop to as little as $25/month for a one- or three-month supply, subject to eligibility and savings caps. This specific savings card excludes government insurance beneficiaries. As with similar programs for other GLP-1 medications, the savings card reduces your copay on top of existing coverage rather than creating coverage where your plan doesn't already include Zepbound, so confirming your plan's actual formulary status is the necessary first step before assuming this pricing applies to you.
Vials vs. the Pre-Filled Pen: Understanding the Tradeoff
Zepbound's self-pay program specifically uses single-dose vials, which is a meaningfully different format from the pre-filled auto-injector pen most insured patients receive. Vials require drawing up the correct dose with a separate syringe, which adds a small manual step compared to simply clicking a pen against your skin. For patients who are comfortable with basic injection technique (something your prescribing provider will walk you through), this isn't usually a significant barrier, but it's worth understanding upfront rather than being surprised by it when your first shipment arrives.
The vial format is specifically why the self-pay program can offer lower pricing than the pen: manufacturing and packaging a single-dose vial is less expensive than the auto-injector pen mechanism, and that manufacturing savings is passed through to the self-pay price. If ease of use matters more to you than the cost savings, ask your provider whether pen-based self-pay options exist at your specific pharmacy, though pricing for the pen format typically runs higher than the vial program across most locations. Many patients who start on vials report that the injection technique becomes routine within the first two or three doses, and some prescribing offices offer a brief demonstration during your first visit specifically to build confidence with the process before you're doing it entirely on your own at home.
Understanding the Refill Window Requirement
The self-pay vial program's reduced pricing is contingent on refilling within a specified window (commonly 45 days) of your previous order. This isn't an arbitrary bureaucratic rule — it's tied to how the program is structured to serve patients on an active, ongoing treatment course rather than infrequent or one-time purchases. If you miss this window, whether due to a delayed refill request, a temporary supply issue, or simply forgetting, your next order may revert to a higher price tier until you're back within the standard cadence expected by the program. Setting a calendar reminder around your specific refill window, similar to how you'd track any other recurring prescription, is the simplest and most reliable way to avoid this pricing reset entirely.
Without Insurance: Manufacturer Self-Pay Vials
Eli Lilly's direct self-pay program offers single-dose vials (requiring self-administration with a syringe rather than the pre-filled pen) at meaningfully reduced cash pricing: commonly around $299/month for the 2.5mg starting dose, $399/month for 5mg, and $449/month for higher therapeutic doses (7.5mg-15mg), provided refills are completed within the program's specified window. Miss that refill window and the price reverts to a higher tier until you re-enroll.
This self-pay program cannot be combined with insurance or the manufacturer's separate savings card — each fill uses one payment method. Medicare and Medicaid beneficiaries can use the self-pay vial program on a cash basis, even though they're excluded from the commercial savings card.
Manufacturer self-pay vials at $299-$449/month are real progress from the $1,086 list price, but pricing still increases as your dose increases — the therapeutic maintenance doses most patients end up on cost more than the starting dose. Luma Health's compounded tirzepatide is $297/month, flat, regardless of dose, with your medical evaluation and provider access included in that price.
How Pricing Changes as Your Dose Increases
One detail worth understanding upfront: the self-pay vial program's tiered pricing means your monthly cost rises as your provider increases your dose during the standard titration schedule. Starting at the 2.5mg introductory dose costs less than the 10mg or 15mg doses many patients eventually reach for their therapeutic maintenance level. This is worth factoring into your budget from the outset rather than being surprised several months into treatment when your price increases — ask your provider or the self-pay program directly what the full pricing ladder looks like across all available doses, not just the starting-dose price often featured prominently in marketing materials.
This dose-based pricing structure is a meaningful point of comparison against flat-rate compounded alternatives, which charge the same price regardless of dose. Depending on where you land on the maintenance dose spectrum, a flat-rate option can end up costing less than the self-pay vial program once you've titrated to your effective therapeutic dose, even though the vial program's starting price looks lower at the outset.
Comparing Self-Pay Vials Against Compounded Tirzepatide
Both paths avoid insurance entirely and both require some degree of self-administration, but they differ in a few practical ways. Manufacturer self-pay vials get you the exact FDA-approved finished product, manufactured in Eli Lilly's own facilities under the same quality standards as the branded Zepbound pen. Compounded tirzepatide, prepared by a licensed 503A pharmacy, contains the same active pharmaceutical ingredient but isn't itself an FDA-approved finished product, with quality depending on the specific compounding pharmacy's standards and licensing. Neither path is inherently the wrong choice; they represent different tradeoffs between regulatory status, pricing structure, and total cost that vary depending on your specific dose and how long you expect to stay in treatment, which is why a direct conversation with your provider about your specific situation matters more than a generic recommendation.
Medicare and the GLP-1 Bridge
Medicare has historically excluded weight-loss-only GLP-1 coverage, though this is changing: a federal Bridge program launched in 2026 offers a pathway to Zepbound coverage at a substantially reduced copay for qualifying beneficiaries with documented obesity and prior authorization. If you're on Medicare, ask your provider specifically about current Bridge program eligibility, since these rules are new and continue to be refined.
Because this program is still relatively new as of 2026, eligibility criteria, documentation requirements, and copay structures may continue to evolve, and different Medicare Advantage plans may implement the Bridge program's provisions somewhat differently. If your provider's office hasn't processed a Bridge program application before, it may be worth asking whether they've had experience with it specifically, or whether they can point you toward Medicare's own current guidance directly, since this is an area where staying current on the latest rules matters more than usual for getting an accurate answer.
Considering a Switch to Compounded Tirzepatide
If you've been managing the self-pay vial program's tiered pricing but find your total cost climbing as your dose has increased, it's worth having a direct conversation with your provider about whether compounded tirzepatide might be a more cost-stable alternative for your specific situation. Compounded options typically use flat pricing that doesn't rise as your dose increases, which can make a meaningful difference for patients who've titrated up to a higher maintenance dose and are watching their monthly cost climb accordingly under the vial program's tiered structure. As with any switch between formulations, this should be a clinical conversation with your prescribing provider rather than a decision made purely on price, taking into account your full treatment history and current regulatory guidelines for compounded GLP-1 medications following the 2024 shortage resolution, which narrowed the legal basis for compounding to cases with a documented individual clinical justification.
Which Path Fits You
The right choice depends on where you are in your treatment course, your current dose, and whether you specifically value the FDA-approved finished product over the cost stability a flat-rate alternative can offer at higher doses. Patients early in treatment at lower doses may find the self-pay vial program's starting price attractive, while patients who've titrated to a higher maintenance dose may find a flat-rate compounded option meaningfully less expensive over the remainder of their treatment course.
- Specifically want the FDA-approved brand Zepbound product
- Are comfortable self-administering from a vial with a syringe
- Don't have insurance coverage for the medication
- Want flat pricing that doesn't increase as your dose does
- Don't have insurance and want predictable monthly cost
- Want ongoing provider access included in the price
Flat pricing,
every dose level
Compounded tirzepatide at $297/month — medical evaluation, provider visits, and shipping all included, no insurance required.
Get Started → Or start your free health assessmentFrequently Asked Questions
The list price is around $1,086/month, but Eli Lilly's self-pay vial program brings it to roughly $299/month for the starting dose up to $449/month for higher therapeutic doses.
Yes. The self-pay program uses single-dose vials rather than the pre-filled auto-injector pen, requiring self-administration with a syringe (sold separately, typically $10-20/month).
No. The manufacturer savings card requires commercial insurance and cannot be stacked with the cash-pay self-pay vial program. Each fill uses one payment method.
It depends on your dose. At starting doses, manufacturer self-pay vials can be similarly priced or slightly less. At higher therapeutic maintenance doses, flat-rate compounded options like Luma Health's $297/month often cost less than the self-pay vial tier for that dose.
Historically, Medicare excluded weight-loss-only coverage, though a federal Bridge program launched in 2026 offers a reduced-copay pathway for qualifying beneficiaries. Rules are actively evolving; verify current eligibility with your plan.
Missing the manufacturer's specified refill window typically reverts your price to a higher tier for that fill. You can usually re-enroll at the lower tier with your next order going forward.
It requires drawing up the correct dose with a separate syringe rather than clicking a pre-filled pen, which is a small additional manual step. Your provider will walk you through the technique, and most patients adjust to it quickly.
Manufacturing and packaging a single-dose vial is less expensive than the auto-injector pen mechanism, and that savings is passed through to the self-pay price.
Set a calendar reminder around your specific refill window (commonly 45 days) so you reorder before it lapses, similar to how you'd track any other recurring prescription.
References
- Eli Lilly and Company. Zepbound (tirzepatide) cost and self-pay information. Lilly.com. 2026. pricinginfo.lilly.com
- U.S. Food and Drug Administration. Prescribing Information for Zepbound (tirzepatide). FDA.gov. 2025. FDA.gov
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- Mercer. National Survey of Employer-Sponsored Health Plans, 2025: GLP-1 coverage findings. Mercer.com. 2025. Mercer.com